Recent News and Upcoming Events

First Light Diagnostics Receives Additional Funding from the Biomedical Advanced Research and Development Authority (BARDA)

Funding Supports Continued Development of the SensiTox™ B. anthracis Toxin Test Chelmsford, MA, October 27, 2020 – First Light Diagnostics, Inc., a developer of breakthrough automated products for the rapid diagnosis and treatment of life-threatening infections, today announced the authorization of a $4 million award from the Biomedical Advanced Research and Development Authority (BARDA), part…

Read More

First Light Diagnostics Names New Chief Financial Officer

Life Sciences Veteran Andrew Wilsack Joins Team Chelmsford, MA (May 28, 2020) – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has appointed Andrew Wilsack as the company’s new CFO. “Andrew’s broad experience across disciplines will be an asset for us,” said David Macdonald,…

Read More

First Light Diagnostics Posters and Abstracts Accepted, Part of ECCMID 2020 Abstract Book

Chelmsford, MA (May 21, 2020) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the acceptance of two posters as part of the 30th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). With global resources focused on combatting the current…

Read More

First Light Diagnostics Receives $1.1 Million ‘Paycheck Protection Program’ Loan Under the CARES Act

CHELMSFORD, Mass., May 19, 2020 – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has acquired a “Paycheck Protection Program” (PPP) loan with the US Small Business Administration (SBA) as part of the US Coronavirus Aid, Relief and Economic Security (CARES) Act. The loan…

Read More

First Light Diagnostics Appoints New Chief Operating Officer

Seasoned Industry Veteran to Take Company Through Next Phase of Operations Chelmsford, MA (May 6, 2020) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has named  Dr. Joanne Spadoro as Chief Operating Officer (COO). Dr. Spadoro is a recognized leader in the in…

Read More

What Sets Us Apart?

Our MultiPath benchtop analyzer is advancing the field of rapid diagnostics in several key areas:

Culture Free Results

Culture Free Results

The MultiPath technology outperforms current culture-based methods by providing pathogen identification results in 30 minutes and antimicrobial susceptibility test results in 4 hours…without a sample culture step.
Hours vs. Days

Hours vs. Days

Culture-free test capabilities make MultiPath the ONLY platform capable of delivering diagnostic results in hours as compared to multiple days required for current, culture-based tests.
Therapy at the Onset of Infection

Therapy at the Onset of Infection

Rapid Diagnostic ID/AST results provide timely, actionable data for clinicians to make the best therapy decisions for their patients at the onset of infection.

Meet the Team

Management Team
Board of Directors
Clinical Advisory
Other Advisors
light-purple-logo

How the First Light Diagnostics MultiPath® Platform Can Help Patients Receive the Right Therapy at the Onset of Infection

Contact First Light Diagnostics

If you have been watching the continued growth and development of this exciting company and would like to to speak in person with David Macdonald, CEO, and Don Straus, CSO, please fill out the form below and we will work with you to coordinate a one on one meeting.



Role in your Organization*







Recent Publications/Posters

(Peer Reviewed Article) A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples
A New Method for Rapid Phenotypic AST Directly from Patient Samples

Recent Industry articles on the Antibiotic Resistance Problem

Menu